Colombia vs Nepal: Average cost of multi drug-resistant tuberculosis treatment
Colombia
1,528 constant 2022 US$
in 2024
Nepal
1,526 constant 2022 US$
in 2024
Colombia rank
32nd
Nepal rank
33rd
Average cost of multi drug-resistant tuberculosis treatment over time
- Colombia
- Nepal
How they compare
Colombia currently reports 1,528 constant 2022 US$ against 1,526 constant 2022 US$ in Nepal, a difference of 2 constant 2022 US$.
The two have swapped places 4 times across 7 shared years of data; in 2018 it was Colombia ahead.
Colombia ranks 32nd and Nepal ranks 33rd of 92 countries.
Across the 2 decades both report, Colombia averaged higher in 1 and Nepal in 1.
Head to head by decade
| Decade | Colombia | Nepal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,500 constant 2022 US$ | 1,165 constant 2022 US$ | 1,335 constant 2022 US$ | Colombia |
| 2020s | 953 constant 2022 US$ | 1,226 constant 2022 US$ | 273.2 constant 2022 US$ | Nepal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Colombia or Nepal?
- Colombia, at 1,528 constant 2022 US$ against 1,526 constant 2022 US$ in Nepal as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Colombia and Nepal?
- 2 constant 2022 US$, with Colombia ahead.
- How many years of comparable data are there for Colombia and Nepal?
- 7 years are reported by both, from 2018 to 2024.
- How do Colombia and Nepal rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Colombia ranks 32nd and Nepal ranks 33rd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.